⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNGX News
Soligenix, Inc. Common Stock
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
globenewswire.com
SNGX
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
globenewswire.com
SNGX
PFE
MRK
BMY
INSM
Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight
prnewswire.com
SNGX
IPH
PFE
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
prnewswire.com
SNGX
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Announces Closing of $7.5 Million Public Offering
prnewswire.com
SNGX
Soligenix Announces Pricing of $7.5 Million Public Offering
prnewswire.com
SNGX